



NEWS RELEASE

For Further Information Contact:

Roy Wolvin

Nymox Pharmaceutical Corporation

800-93NYMOX

www.nymox.com

For Immediate Release:

Nymox's NX-1207 Offers a New and Attractive Approach to the Treatment of Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, NJ (February 20, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an outline today of the outstanding potential the Company's proprietary drug, NX-1207, has for the treatment of the common condition of enlarged prostate or benign prostatic hyperplasia (BPH).

In clinical trials, NX-1207 treatment for BPH has shown a superior safety and efficacy profile compared to those reported for current FDA approved BPH treatments. In two multi-center Phase 2 U.S. prospective randomized blinded clinical trials, the aggregated mean improvement in BPH Symptom Score for 2.5 mg NX-1207 was 10.3 points (n=85) 3 months after a single treatment. Follow-up studies have shown evidence of a durable benefit of 2 years or more for many patients.

This treatment benefit compares favorably to the mean symptom score improvement typically found after 3 months for currently approved BPH medications such as alpha blockers (in the 5 point range) and 5 alpha reductase inhibitors (in the 3 point range). Patients treated with NX-1207 did not report any of the sexual side effects such as loss of libido associated with the use of 5 alpha reductase inhibitors, and erectile dysfunction associated with alpha blockers.

Studies of alpha blockers and 5 alpha reductase inhibitors have shown that these approved drugs are stopped by a large percentage of men who are prescribed them, due to intolerance of the side effects of the drugs such as dizziness, weakness, erectile dysfunction, loss of libido, retrograde ejaculation, gynecomastia, syncope, and many other frequent problems.

NX-1207 treatment had mean improvement in symptom score comparable to minimally invasive surgical therapies for BPH (MIST) such as transurethral microwave or needle ablation, which require sedation or anesthesia. NX-1207 treatment was not associated with such adverse effects as retrograde ejaculation and urethral damage reported for MIST.

NX-1207 is administered by intraprostatic injection in a single in-office procedure by a urologist lasting a matter of minutes. There is no anesthesia involved and no catheterization is required. NX-1207 is a novel proprietary new chemical entity with long term patent protection.

BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems, and can cause acute urinary retention requiring immediate medical attention.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###